FNDC5 and Obesity: Unfortunately, there are limited data associated with various controversial findings regarding the short- and long-term monitoring of irisin and the therapeutic effect on its serum levels depending on the etiology of HF and coexisting comorbidities, including T2DM, obesity and stable coronary artery disease [56,57].